Physician profile
Sameer M Naseeruddin
NPI 1578627964
$13,601.85
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $824 · 2021: $11K · 2022: $411 · 2023: $319 · 2024: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11,011.00 | 2019-2021 | |
| Lilly USA, LLC | $371.10 | 2019-2024 | Mounjaro, Trulicity |
| Tactile Systems Technology INC | $353.17 | 2019-2024 | Flexitouch Plus, Entre Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.93 | 2020-2023 | Jardiance |
| Galderma Laboratories, L.P. | $201.29 | 2019-2021 | |
| Pfizer INC. | $174.11 | 2020-2021 | |
| Amarin Pharma, INC. | $172.97 | 2020 | |
| Medtronic, INC. | $152.43 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $145.15 | 2022 | |
| Merz North America, INC. | $124.64 | 2022-2023 | Xeomin |
| Novo Nordisk INC | $102.45 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $94.58 | 2019-2020 | |
| Medtronic Vascular, INC. | $82.51 | 2020 | |
| Glaxosmithkline, LLC. | $81.37 | 2022-2023 | Boostrix |
| Angiodynamics, INC. | $67.55 | 2019-2023 | Venacure 1470 Pro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $63.05 | 2020-2022 | |
| Exact Sciences Corporation | $41.25 | 2023 | Cologuard Collection Kit |
| Abbvie INC. | $27.45 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.75 | 2022 | |
| Biocompatibles, INC. | $16.41 | 2019 | |
| Hologic Sales and Service, LLC | $15.25 | 2019 | |
| Merck Sharp & Dohme LLC | $14.53 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.61 | 2024 | Xifaxan |
| Romark Laboratories, Lc | $8.76 | 2019 | |
| Venclose INC. | $5.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Naseeruddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.